REMICADE Phase 3 data show rapid, significant, long-term psoriasis improvement

Phase 3 data show treatment with REMICADE (infliximab) resulted in rapid, significant improvement and long-term response in patients with moderate to severe plaque psoriasis. Findings from the EXPRESS II trial, a placebo-controlled, dose-ranging study of REMICADE 3 mg/kg and 5 mg/kg, showed that every eight week maintenance therapy resulted in greater long-term skin clearance compared with "as-needed" therapy regimens within each dose. At week 10, after infusions at weeks 0, 2 and 6, 70 percent of patients treated with REMICADE 3 mg/kg and 75 percent of patients receiving 5 mg/kg achieved at least 75 percent improvement in psoriasis as measured by Psoriasis Area Severity Index (PASI 75), compared with two percent of patients receiving placebo (P < 0.001). At week 50, patients receiving REMICADE 5 mg/kg every eight-week maintenance therapy achieved the highest level of sustained PASI improvement with the majority of the patients achieving PASI 75 versus the REMICADE 3 mg/kg eight-week maintenance therapy and the REMICADE 3 mg/kg and 5 mg/kg "as-needed" therapy regimens. Results from EXPRESS II and the previous Phase 3 EXPRESS study were presented today at the 64th annual American Academy of Dermatology meeting.

"We now have data showing that the majority of patients receiving scheduled REMICADE maintenance therapy achieved long-term clinical response in psoriasis, a lifelong, chronic inflammatory disease" said Alan Menter, MD, chairman, Division of Dermatology, Baylor University Medical Center, and lead study investigator. "These findings support previous clinical results and show that patients treated with REMICADE achieved rapid and marked improvement in the moderate to severe category of psoriasis, which impacts the lives of nearly two million Americans."

Consistency of response of REMICADE 5 mg/kg maintenance therapy: Data from EXPRESS and EXPRESS II
In order to evaluate the consistency of response across both Phase 3 studies

Contact: Michael Parks
Centocor, Inc.

Page: 1 2 3

Related biology news :

1. Data in New England Journal of Medicine show benefits of REMICADE in ulcerative colitis patients
2. Active psoriatic arthritis patients on REMICADE achieve major clinical response in arthritis
3. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
4. Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID
5. Oncolytics Biotech Inc. proceeds to initiate US Phase II sarcoma clinical trial
6. The Parkinsons Institute to conduct Phase III Clinical Trial of creatine for Parkinsons disease
7. Phase III trials of cellulose sulfate microbicide for HIV prevention closed
8. Phylonix awarded National Science Foundation Phase II SBIR for zebrafish screening
9. Kentucky first state to match federal SBIR-STTR Phase 1 and Phase 2 grants
10. Acorda announces positive Phase 3 Fampridine-SR study in people with multiple sclerosis
11. New Phase 3 data show potential benefits of Aranesp dosed every three weeks for CIA

Post Your Comments:

(Date:10/3/2019)... ... 02, 2019 , ... Personalized Stem Cells, Inc (“PSC”), a human ... approved clinical trial for stem cell treatment of knee osteoarthritis . The successful enrollment ... a subsidiary of VetStem Biopharma. , PSC CEO, Michael Dale, stated, “We are proud ...
(Date:9/30/2019)... ... September 30, 2019 , ... RoosterBio ... stem/stromal cell (hMSC) biomanufacturing systems, today announced it has received patent approval ... formats (patent number AU 2015259373). This new patent adds intellectual property (IP) ...
(Date:9/25/2019)... ... September 25, 2019 , ... Deep Science Ventures (DSV), a ... world’s largest independent funder of cancer research. , Deep Science Ventures was founded to ... view of the opportunity from the start, both at the industry and biological level. ...
Breaking Biology News(10 mins):
(Date:10/3/2019)... , ... October 01, 2019 , ... Cheyenne is a ... Mimi, Cheyenne’s owner, owns and operates Rebel’s Run , which offers riding ... favorite amongst students and trail riding guests. Mimi describes her as her “go ...
(Date:10/3/2019)... BOSTON (PRWEB) , ... October 03, 2019 , ... Yesterday, ... 2-3, Asymmetrex founder and director, James L. Sherley, M.D., Ph.D., discussed important ... To an attendee audience including both developers and suppliers of clinical trials, in ...
(Date:9/24/2019)... (PRWEB) , ... September 24, 2019 , ... ... stem cell company, has completed training and site qualification for clinical trial sites ... of recruitment and screening of potential clinical trial participants. , Clinical trial sites ...
(Date:9/17/2019)... ... September 17, 2019 , ... Tucker, a Labrador retriever, was just a puppy ... was limping and lame on his right hip and elbow. At one year of ... “the worst case the vet had seen.” He was prescribed pain medications, both oral ...
Breaking Biology Technology:
Cached News: